29 results
424B3
IKT
Inhibikase Therapeutics Inc
4 Apr 23
Prospectus supplement
4:57pm
green staining in the images at both 50 and 150 mg/kg treatment (Fig. 3). Thus, functional reversal in the gut is accompanied by clearance of toxic … (Rabbit Polyclonal; Green) and VaCht (Goat polyclonal; Red) and with appropriate secondary antibodies. The tissues were then mounted with Prolong Anti
POS AM
xkkio
31 Mar 23
Prospectus update (post-effective amendment)
4:11pm
PRE 14A
t2om88nicnyjfzdt s1
21 Apr 22
Preliminary proxy
4:33pm
8-K
EX-99.1
pdnr1p2bwy6jo9yfn
21 Apr 22
Regulation FD Disclosure
4:19pm
8-K
EX-99.1
6fzl l5argg4hfjja
24 Mar 22
Regulation FD Disclosure
9:17am
8-K
EX-99.1
1s516aq al
20 Jan 22
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson’s and Related Disorders 1Q 2022 BUSINESS PRESENTATION IKT
4:10pm
8-K
EX-99.1
kja5crjmkwz jwxbppt
19 Oct 21
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson’s and Related Disorders 4Q 2021 BUSINESS PRESENTATION IKT
5:03pm
8-K
EX-99.1
pq3wuj
17 Aug 21
Regulation FD Disclosure
5:02pm
424B4
h8fttcrovfsj1egdh
17 Jun 21
Prospectus supplement with pricing info
4:31pm
DRS
xz68o
2 Jun 21
Draft registration statement
12:00am
8-K
EX-99.1
jrs94cxw
1 Jun 21
Regulation FD Disclosure
7:30am
DEFA14A
owdjci1lm 7yiylza3
30 Apr 21
Additional proxy soliciting materials
5:21pm
DEF 14A
1wsj6i k7vg
30 Apr 21
Definitive proxy
5:20pm